Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in pediatric ulcerative colitis
NCT02632175Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of adalimumab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02632175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632175.